Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma

Oncology (Williston Park). 2019 Apr 15;33(4):132-6.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use*
  • B7-H1 Antigen / antagonists & inhibitors
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / surgery
  • Chemotherapy, Adjuvant
  • Cystectomy / methods
  • Drug Therapy, Combination / methods
  • Humans
  • Immunotherapy
  • Interleukin-2 / analogs & derivatives
  • Interleukin-2 / therapeutic use
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Nivolumab / therapeutic use
  • Polyethylene Glycols / therapeutic use
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
  • B7-H1 Antigen
  • Interleukin-2
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • Polyethylene Glycols
  • atezolizumab
  • bempegaldesleukin
  • pembrolizumab